School of Medicine
Showing 451-460 of 623 Results
-
Matthew Porteus
Sutardja Chuk Professor of Definitive and Curative Medicine
BioDr. Porteus was raised in California and was a local graduate of Gunn High School before completing A.B. degree in “History and Science” at Harvard University where he graduated Magna Cum Laude and wrote an thesis entitled “Safe or Dangerous Chimeras: The recombinant DNA controversy as a conflict between differing socially constructed interpretations of recombinant DNA technology.” He then returned to the area and completed his combined MD, PhD at Stanford Medical School with his PhD focused on understanding the molecular basis of mammalian forebrain development with his PhD thesis entitled “Isolation and Characterization of TES-1/DLX-2: A Novel Homeobox Gene Expressed During Mammalian Forebrain Development.” After completion of his dual degree program, he was an intern and resident in Pediatrics at Boston Children’s Hospital and then completed his Pediatric Hematology/Oncology fellowship in the combined Boston Chidlren’s Hospital/Dana Farber Cancer Institute program. For his fellowship and post-doctoral research he worked with Dr. David Baltimore at MIT and CalTech where he began his studies in developing homologous recombination as a strategy to correct disease causing mutations in stem cells as definitive and curative therapy for children with genetic diseases of the blood, particularly sickle cell disease. Following his training with Dr. Baltimore, he took an independent faculty position at UT Southwestern in the Departments of Pediatrics and Biochemistry before again returning to Stanford in 2010 as an Associate Professor. During this time his work has been the first to demonstrate that gene correction could be achieved in human cells at frequencies that were high enough to potentially cure patients and is considered one of the pioneers and founders of the field of genome editing—a field that now encompasses thousands of labs and several new companies throughout the world. His research program continues to focus on developing genome editing by homologous recombination as curative therapy for children with genetic diseases but also has interests in the clonal dynamics of heterogeneous populations and the use of genome editing to better understand diseases that affect children including infant leukemias and genetic diseases that affect the muscle. Clinically, Dr. Porteus attends at the Lucille Packard Children’s Hospital where he takes care of pediatric patients undergoing hematopoietic stem cell transplantation.
-
George A. Poultsides, MD, MS
Stanford Department of Surgery Professor
Current Research and Scholarly InterestsClinical trials of experimental diagnostics and therapeutics; outcomes analysis following combined modality treatment of hepatic, pancreatic, and gastrointestinal malignancies.
-
Guillem Pratx
Associate Professor of Radiation Oncology (Radiation Physics)
Current Research and Scholarly InterestsThe Physical Oncology Lab is interested in making a lasting impact on translational cancer research by building novel physical tools and methods.
-
Judith Prochaska
Senior Associate Vice Provost, Clinical Research Governance and Professor of Medicine (Stanford Prevention Research Center)
Current Research and Scholarly InterestsDr. Prochaska's clinical trials research focuses on developing and testing evidence-based interventions for tobacco, other substance use, physical activity, and diet. She has led randomized controlled trials of treatments that combine motivational, behavioral, and pharmacologic strategies, including use of telemedicine, therapeutic relational agents, social-media–supported interventions, and tailored programs for socio-demographically diverse and at-risk groups to advance population health.
-
Carla Pugh, MD, PhD
Thomas Krummel Professor
Current Research and Scholarly InterestsThe Technology Enabled Clinical Improvement (T.E.C.I.) Center is a multidisciplinary team of researchers dedicated to the design and implementation of advanced engineering technologies that facilitate data acquisition relating to clinical performance.
-
Lei (Stanley) Qi
Associate Professor of Bioengineering
BioDr. Lei (Stanley) Qi (publishes as Lei S. Qi) is an Associate Professor in the Department of Bioengineering at Stanford University, an Institute Scholar at Sarafan ChEM-H, and a Chan Zuckerberg Biohub Investigator. Trained in physics and mathematics (Tsinghua University) and bioengineering (UC Berkeley), he was a Systems Biology Fellow at UCSF before joining the Stanford faculty in 2014.
Qi is a pioneer in CRISPR technology and genome engineering. His lab created the first nuclease-deactivated Cas9 (dCas9) for targeted gene regulation, establishing CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa). Since then, his group has expanded CRISPR from an editing tool into a platform for programmable control of dynamic and spatial cell state, integrating scalable perturbation, live-cell and super-resolution imaging, and computation-guided design. This work has produced technologies for multiplexed transcriptome regulation, programmable 3D genome organization, spatial RNA logistics control, and real-time visualization of chromatin and transcriptional events in living cells.
A distinctive focus of the Qi lab is closed-loop biology, combining perturbation with high-content measurements to infer mechanisms and iteratively refine control strategies. The lab develops platforms spanning multiplexed transcriptional and epigenetic control, spatial genome–transcriptome organization, and quantitative live-cell imaging of chromatin and transcriptional dynamics. A compact nuclease-dead CRISPR epigenetic editor from this technology lineage has advanced to first-in-human clinical testing for facioscapulohumeral muscular dystrophy (FSHD; NCT06907875), underscoring the translational potential of principle-driven control systems.
Beyond single-cell control, Qi’s lab is building a framework for synthetic cell–cell communication, with particular emphasis on the bidirectional interplay between immune cells and neurons. The lab’s goal is to move beyond describing molecular parts to discovering fundamental control principles in living systems: how regulatory landscapes create stable states and memory, how spatial genome–RNA organization shapes dynamic responses, and how engineered cell–cell interactions can generate emergent multicellular behaviors. By integrating experimental bioengineering with computation and machine learning, the lab aims to identify generalizable rules linking molecular programs to systems-level physiology and disease trajectories and to translate those rules into next-generation therapeutic cells.
